The European MAPPYACTS Trial: Precision Medicine Program in Pediatric and Adolescent Patients with Recurrent Malignancies
Year: 2022
Type: article
Abstract: ABSTRACT: MAPPYACTS (NCT02613962) is an international prospective precision medicine trial aiming to define tumor molecular profiles in pediatric patients with recurrent/refractory malignancies in order to suggest the most adapted salvage treatment. From February 2016 to July 2020, 787 patients were included in France, Italy, Ireland, and Spain. At least one genetic alteration leading to a targeted treatment suggestion was identified in 436 patients (69%) with successful sequencing; 10% of these alterations were considered "ready for routine use." Of 356 patients with follow-up beyond 12 months, 107 (30%) received one or more matched targeted therapies-56% of them within early clinical trials-mainly in the AcSé-ESMART platform trial (NCT02813135). Overall, matched treatment resulted in a 17% objective response rate, and of those patients with ready for routine use alterations, it was 38%. In patients with extracerebral tumors, 76% of actionable alterations detected in tumor tissue were also identified in circulating cell-free DNA (cfDNA). SIGNIFICANCE: MAPPYACTS underlines the feasibility of molecular profiling at cancer recurrence in children on a multicenter, international level and demonstrates benefit for patients with selected key drivers. The use of cfDNA deserves validation in prospective studies. Our study highlights the need for innovative therapeutic proof-of-concept trials that address the underlying cancer complexity. This article is highlighted in the In This Issue feature, p. 1171.
Source: Cancer Discovery
Authors: Pablo Berlanga, Gaelle Pierron, Ludovic Lacroix, Mathieu Chicard, Tiphaine Adam de Beaumais, Antonin Marchais, Anne C. Harttrampf, Yasmine Iddir, Alicia Larive, Aroa Soriano Fernandez, Imene Hezam, Cecile Chevassus, Virginie Bernard, Sophie Cotteret, Jean-Yves Scoazec, Arnaud Gauthier, Samuel Abbou, Nadege Corradini, Nicolas André, Isabelle Aerts, Estelle Thebaud, Michela Casanova, Cormac Owens, Raquel Hladun-Alvaro, Stefan Michiels, Olivier Delattre, Gilles Vassal, Gudrun Schleiermacher, Birgit Geoerger
Institutions: Université Paris-Saclay, Institut Gustave Roussy, Institut Curie, Centre National de la Recherche Scientifique, Inserm, Analyse moléculaire, modélisation et imagerie de la maladie cancéreuse, Université Paris Sciences et Lettres, Centre de recherche en Epidémiologie et Santé des Populations, Universitat Autònoma de Barcelona, Vall d'Hebron Institut de Recerca, Institut d’Hématologie et d’Oncologie Pédiatrique, Centre Léon Bérard, Aix-Marseille Université, Assistance Publique Hôpitaux de Marseille, Centre de Recherche en Cancérologie de Marseille, Hôpital de la Timone, Centre Hospitalier Universitaire de Nantes, Fondazione IRCCS Istituto Nazionale dei Tumori, Children's Health Ireland at Crumlin, Vall d'Hebron Hospital Universitari
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: hybrid
Funders: Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Celgene, Les Laboratories Pierre Fabre, Société Française de lutte contre les Cancers et les leucémies de l'Enfant et de l'Adolescent, Yuhan, Fondation ARC pour la Recherche sur le Cancer, Institut National Du Cancer, Institut Gustave-Roussy, Servier, Ipsen, Fundación Fero, Genentech, National Cancer Institute
OpenAlex ID: W4220935578
